| http://www.w3.org/ns/prov#value | - The Company's lead therapeutic candidate is a novel synthetic broad spectrum anti-bacterial proven to be effective in killing a wide range of gram-positive, gram-negative, and antibiotic-resistant bacteria and is expected to enter the clinic in 2013.This press release contains forward-looking statements that can be identified by terminology such as expects", potential, "suggests", may, will
|
